Jaguar Health Receives Fee Waivers from FDA
The FDA granted Jaguar Health's family company Napo Pharmaceuticals a waiver of the PDUFA fee for Mytesi (crofelemer) for fiscal year 2027. Jaguar also received a fee waiver from FDA's Center for Veterinary Medicine for Canalevia-CA1, its conditionally approved drug for chemotherapy-induced diarrhea in dogs, for fiscal 2027. Both products are commercialized in the U.S.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.